Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00101114 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: sorafenib tosylate
BIOLOGICAL: recombinant interferon alfa-2b
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)